目的：探讨上海市公共卫生临床中心（以下简称“我院”）核苷类抗病毒药的应用现状及趋势。方法：采用回顾性调查方法，对2013—2015年我院核苷类抗病毒药的销售金额、用药频度和限定日费用等进行统计分析。结果：2013—2015年我院核苷类抗病毒药的销售金额呈逐年增长趋势；恩替卡韦销售金额占核苷类抗病毒药销售金额的比例最高，其年销售金额均＞3000万元，占比均＞60％。阿德福韦酯、恩替卡韦、替比夫定的用药频度逐年增长；替比夫定用药频度的增长最为明显，从2013年的369796增至2015年的479899。除拉米夫定的限定日费用有一点波动外，其余药物的限定日费用均有一定程度的下降；恩替卡韦限定日费用的下降最具代表性，从2013年的30．37元降至2015年的22．46元。阿德福韦酯、拉米夫定的市场占有份额小但使用频率较高，社会效益大于经济效益；恩替卡韦有较好的社会效益和经济效益；替比夫定具有较好的经济性。结论：我院核苷类抗病毒药的应用正逐步规范化。%OBJECTIVE:To probe into the application status and trend of nucleoside antiviral agent in Shanghai Public Health Clinical Center( hereinafter referred to as “our hospital”) .METHODS: By retrospective investigation method, statistical analysis was conducted on the consumption sum, defined daily dose system ( DDDs) and defined daily cost ( DDC ) of nucleoside antiviral agent during 2013-2015 .RESULTS: The consumption sum of nucleoside antiviral agent during 2013-2015 were in a increase trend year by year.The ratio of consumption sum of entecavir versus nucleoside antiviral agent took the lead, the annual consumption was >30 million yuan, the ratio was >60%. DDDs of adefovir dipivoxil, entecavir and telbivudine was in a increase trend year by year.And the increase of telbivudine was significant, from 369 796 in 2013 to 479 899 in 2015.Except for the DDC of lamivudine had changed a little, the DDC of other drugs had decreased to some extent.DDC of entecavir was the most representative one, from 30.37 yuan in 2013 to 22.46 yuan in 2015.The market share of adefovir dipivoxil and lamivudine was small, while the application rate was relatively high, the social benefit was greater than the economic benefit.Entecavir had better social and economic benefits; and telbivudine had obvious economic benefits.CONCLUSIONS: The application of nucleoside antiviral agent in our hospital is gradually standardized.
展开▼
